2nd Quarter - Report

NOVO NORDISK INC. for NOVO NORDISK INC.

Firm
Client
Income
—
Expenses
$640,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues related to patent litigation and patent assertion entities (PAEs) aka patent trolls

Contacted: Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); SENATE; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA)

Health Issues HCR

National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), Prevention and Public Health Fund, AHRQ and USPSTF diabetes screening standards;diabetes issues in Healthy People 2020 and the Office of Disease Prevention and Health Promotion (ODPHP); H.R. 1074 and S. 539 National Diabetes Clinical Care Commission Act of 2013; human growth / rare disorders awareness; H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); gestational diabetes; diabetes disparities; H.R. 351 and S. 351 Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal)

Contacted: SENATE; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1074 (113th), S. 539 (113th), H.R. 8 (113th), H.R. 351 (113th), S. 351 (113th)

Medicare/Medicaid MMM

H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011, H.R. 8 American Taxpayer Relief Actof 2012, and H.R. 1588 and S. 740 Medicare Drug Savings Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 and S. 945 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare);Medicare diabetes screening generally; S. 1184 and H.R. 2415 Treat and Reduce Obesity Act of 2013; Physician Quality and Reporting System (PQRS)

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Natl Institutes of Health (NIH); Executive Office of the President (EOP); Veterans Affairs, Dept of (VA); Centers For Disease Control & Prevention (CDC)

Bills named: S. 452 (113th), S. 740 (113th), H.R. 2415 (113th), H.R. 962 (113th), H.R. 1274 (113th), S. 945 (113th), H.R. 8 (113th), H.R. 1257 (113th), H.R. 1588 (113th), S. 1184 (113th)

Budget/Appropriations BUD

Issues related to Medicare Part D, FDA and patents in S. Con. Res. 8 FY14 Senate Budget Resolution; H. Con. Res. 25 House Budget Resolution; H.R. 2663 The Preventative Health Savings Act of 2013 (Modernizing CBO scoring estimates with respect to preventive health legislation); National Diabetes Prevention Program in H.R. 933 -- FY13 Consolidated and Further Continuing Appropriations Act and S. 1284 FY14 Depts. of Labor, Health and Human Services, and Education Appropriations Act

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Executive Office of the President (EOP); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA)

Bills named: H.Con.Res. 25 (113th), H.R. 2663 (113th), S. 1284 (113th), H.R. 933 (113th), S.Con.Res. 8 (113th)

Pharmacy PHA

H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013 and S.959 Pharmaceutical Compounding Quality and Accountability Act (for track and trace supply chain provisions); issues regarding biosimilars; 340B

Contacted: Executive Office of the President (EOP); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA)

Bills named: S. 959 (113th), H.R. 1919 (113th)

Trade (domestic/foreign) TRD

EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property); Trans-Pacific Partnership (TPP) (intellectual property)

Contacted: Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Executive Office of the President (EOP); Veterans Affairs, Dept of (VA); SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

H.R. 8 American Taxpayer Relief Act (R&D tax credit) of 2012 (R&D credit); H.R. 2052 and S. 1023 Global Investment in American Jobs Act

Contacted: Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Veterans Affairs, Dept of (VA); SENATE; Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2052 (113th), H.R. 8 (113th), S. 1023 (113th)

Veterans VET

Issues related to insulin pen safety and access in the VA

Contacted: Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); SENATE; Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
NOVO NORDISK FONDEN (FOUNDATION) Denmark Denmark 25.5% —
NOVO NORDISK A/S Denmark Denmark 100.0% —
NOVO A/S Denmark Denmark 25.5% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.